Abstract: Clinical significance of potential interaction between warfarin and statins is unclear. Our objective was to determine whether use of statins as a class or use of simvastatin modulates the rate of bleeding requiring hospitalization among new warfarin users. Using Finnish healthcare databases, we identified a cohort of 101,588 warfarin initiators between 1 January 2009 and 30 June 2012. By the end of 2012, these patients accumulated 92,695 person-years of exposure to warfarin-only and 60,253 years of exposure to warfarin-with-statin. The outcome was a composite of gastrointestinal, intracranial or other bleeding leading to hospitalization. A Poisson generalized estimating equation model was employed to estimate rate ratios (RR) and their 95% confidence intervals (CI) for exposure to warfarin-with-statin compared to warfarin-only and to allow multiple episodes per patient and time-dependent covariates. In multivariable models, we found no difference in the bleeding rate in association with exposure to any statin (multivariable-adjusted RR = 0.98, 95% CI 0.89-1.07) or to simvastatin (RR = 1.01, 95% CI 0.91-1.11) with warfarin compared to exposure to warfarin-only. We conclude that concomitant use of statins and warfarin was not associated with an increased rate of bleeding requiring hospitalization.
Despite the increasing use of non-vitamin K antagonist anticoagulants or direct oral anticoagulants (DOACs), warfarin has maintained its role among first-choice oral anticoagulants [1] . In clinical practice, narrow therapeutic index and several drug-drug interactions complicate the use of warfarin as most users are older people presenting with multimorbidity and polypharmacy [2] .
Both warfarin and statins are prescribed for the prevention and treatment of thromboembolic conditions, and their coprescribing is common. For example, in Finland in 2010, 49% of all warfarin users were prescribed lipid-modifying medications, mostly statins, during the preceding year [3] . Statins may have lipid-independent pleiotropic effects, including inhibitory effects on platelet activation and reduction in the procoagulant state [4] . Accordingly, some randomized trials have found reduction in the risk of venous thromboembolism for statin use [5] . Thus, the concomitant use of warfarin and statins could predispose patients for potentially harmful drug-drug interactions.
Case reports have suggested a clinically significant interaction of warfarin with simvastatin [6, 7] and rosuvastatin [8] . However, the results of systematic studies on potential vitamin K antagonist-statin interaction are inconsistent. Anticoagulant activity has been found to be increased [9, 10] or unchanged [11, 12] during their concomitant use. A parallel-group study in patients on warfarin showed lower daily warfarin dose requirements in patients on concomitant simvastatin compared to those on warfarin alone; the presence of a pharmacokinetic interaction was claimed [9] . In another study, patients stabilized on warfarin received 80 mg atorvastatin daily for 2 weeks, but no clinically significant effect on anticoagulant activity was noted [11] . In healthy volunteers, rosuvastatin 40 mg/day for one week did not alter the effects of warfarin on laboratory markers of blood clotting [12] . A recent Dutch study concluded that initiation of statins had a minor, although statistically significant, decreasing effect on phenprocoumon and acenocoumarol doses [10] .
Also, the results from large database studies have been mixed. Initiation of statin use among warfarin users has been found to increase the risk of gastrointestinal bleeding [13] or to have no effect on the risk of a composite outcome including gastrointestinal or intracranial bleeding [14] . The bleeding risk seemed to be even lower in patients who used statins and warfarin concomitantly for more than 6 months than in those using warfarin-only [13, 14] . A recent study including over 200,000 US Medicaid beneficiaries [15] focused on patients who were newly exposed to both warfarin and a lipid-modifying medication. Compared to exposure to pravastatin and warfarin, exposure to fibrates and warfarin was associated with an increased risk of bleeding during the first 30 days of the concomitant use. No differences were observed across patients exposed to various statins with warfarin throughout the first 6 months. The authors interpreted the results as consistent with null association for statins.
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We performed a nationwide cohort study in a country with a homogenous population and universal health care and medication reimbursement systems to determine whether statins as a class or simvastatin, the most widely used statin in Finland in the mid-2010s [16] , modulate the rate of bleeding requiring hospitalization in new warfarin users.
Materials and Methods
We conducted a cohort study among patients who initiated warfarin use in January 2009-June 2012 in Finland [2] . Instead of focusing on new use of statins, we anchored our cohort at the time of warfarin initiation. We assumed this time to correspond to the time when clinicians and patients make decisions about which other medications to continue or discontinue [17] . The data were sourced from nationwide prescription fill and hospitalization databases and linked using the unique identity number assigned to every Finnish resident.
Data sources. Medication use was ascertained through the Prescription Register, a prescription claims database maintained by the Social Insurance Institution (SII) of Finland. The Prescription Register includes information on reimbursed prescription fills from all Finnish community pharmacies. For each dispensed medication, the Anatomical Therapeutic Chemical (ATC) classification code and the strength, quantity dispensed (as tablets or other units and defined daily doses, DDD) and dispensing date are recorded. Medication use in hospitals and public nursing homes where medications are supplied by the service provider is not captured in the database. Information on bleeding events, indications and comorbidities was obtained from the Care Register for Health Care maintained by the National Institute for Health and Welfare. This database contains discharge diagnoses (10th version of the International Classification of Diseases or ICD-10 codes), procedure codes (Nordic Medico-Statistical Committee or NOMESCO classification) and admission and discharge dates on inpatient and outpatient visits to all Finnish hospitals. Additional comorbidity data were obtained from the SII Register for Entitlements to Special Refund which includes information on patients with certain severe, chronic conditions, such as diabetes and coronary artery disease entitling the patient to higher than regular medication reimbursement.
Warfarin initiators. Using data from the Prescription Register, we identified patients who initiated warfarin therapy between 1 January 2009 and 30 June 2012. An initiator was defined as a person who filled a prescription for warfarin (ATC code B01AA03) during the study period after not having filled any such prescription for at least 365 days. We excluded patients who had long-term institutional or hospital care episodes (lasting ≥90 days) overlapping with the 365-day baseline period to confirm that initiators had no previous warfarin use during long-term institutional or hospital care.
Exposures. In Finland, warfarin is available in tablet strengths of 3 and 5 mg and in packs of 100 tablets only. As the data from the Prescription Register do not include information on the prescribed dose nor on days' supply dispensed, we assigned a fixed duration of 180 days to each warfarin fill. This allows for doses less than one tablet per day, periodic dose adjustments and interruptions in home medication for various reasons. A warfarin treatment episode was assumed to be ongoing from the date of the first prescription fill until a gap of 180 days or more occurred between consecutive prescription fills. Each warfarin initiator could have one or more treatment episodes. That is, if a warfarin initiator filled the second prescription on day 182 since initiation, this date was defined as the start date of the second warfarin episode, and day 181 was defined as unexposed to warfarin.
We considered statins (ATC codes C10AA, C10BA02) as a class and simvastatin (C10AA01) also individually. A dosage assumption of 1 tablet per day was used for all statins [18] , and the duration of a prescription fill was calculated as 1.5 times the number of dispensed tablets to allow for non-adherence. A statin episode was assumed to continue until 1.5 times the days covered by the last statin fill had passed. That is, if the last statin fill was for 60 tablets, the episode continued 90 days since the fill date. Each patient could have several statin episodes. For all other medications considered, the number of DDDs included in a prescription fill multiplied by 1.5 was used to estimate the duration of treatment episodes. Warfarin users were considered as exposed to potential interaction during the overlap of warfarin episodes and treatment episodes for other medications regardless of which one came first.
Outcome. A bleeding event was defined as hospitalization for a composite of gastrointestinal, intracranial or other major bleeding identified on the basis of primary discharge diagnosis (table S1 ). The outcome definition was adapted from previous research [2, 19] .
Confounders. Potential confounders were measured prior to warfarin initiation (length of the baseline period varied between 30 days and 7 years) and then annually so that temporal ordering between confounders, exposures and outcome was preserved. A pre-defined set of potential confounders included assumed indications for warfarin therapy (atrial fibrillation, mechanical heart valve, venous thrombosis, pulmonary embolism, heart failure, ischaemic stroke or transient ischaemic attack), bleeding history, Charlson comorbidity index [20] , individual comorbidities potentially associated with bleeding risk (ascertained using information on hospitalizations, entitlements to special refunds or prescription refills and combinations of these), number of hospital days, number of distinct medications in use and demographic variables. table S1 describes data sources and operationalizations for the final set of confounders.
Analyses. Descriptive data are presented as means (AE standard deviations, S.D.) and medians (interquartile ranges, IQR) for continuous variables and as proportions for categorical variables. Each warfarin initiator was followed up until an outcome event, admission to institutional or hospital care lasting for ≥90 days (which leads to ineligibility for medication reimbursements), initiation of a DOAC, death or the administrative end of the study (31 December 2012) whichever came first. The rates of bleeding events per person-years were calculated for warfarin-only and warfarin-with-statin episodes. Using person-time as the unit of analysis, we employed a Poisson generalized estimating equation model to allow multiple episodes per patient and time-dependent covariates. The logarithm of person-years was used as an offset, and robust standard errors were calculated. Firstly, the exposure variable (warfarin-with-statin versus warfarinonly) alone was included in the model to obtain a crude rate ratio (RR). Then, candidate confounders from the pre-defined set were added one-by-one to the crude model. If the regression coefficient of the exposure variable changed more than 5%, the covariate in question was included in the final multivariable model. Continuous covariates were categorized to allow nonlinear associations. Collinearity of the multivariable model was checked, and a covariate was excluded if the variance inflation factor was above 5.
We tested the robustness of our results in several sensitivity analyses as follows: (1) due to well-known increase in the bleeding risk associated with clopidogrel [21] , the bleeding rates associated with exposure to warfarin-with-clopidogrel, warfarin-with-any statin, warfarin-with-clopidogrel and any statin compared to exposure to warfarin-only were estimated. (2) Following the approach by Vitry et al. [22] , follow-up days with exposure to other potentially interacting medications, including non-steroidal anti-inflammatory drugs (NSAIDs) and selective serotonin reuptake inhibitors (SSRI), or clopidogrel, were excluded from the main analysis. In addition, days on NSAIDs and SSRIs were excluded from the first sensitivity analysis. (3) Instead of 180 days, the fixed duration of a warfarin prescription was set to 111 days, estimated by the waiting time distribution method [2] . (4) To restrict the study to incident outcome, warfarin initiators with inpatient or outpatient visits to hospital with a primary discharge diagnosis of gastrointestinal, intracranial or other bleeding during the 180 days preceding and including the day of warfarin initiation were excluded. (5) The definition of a bleeding event was expanded to include visits to hospital outpatient clinics not requiring an overnight stay. (6) The first 180 days of follow-up were excluded which means also that all patients with only one warfarin prescription fill and those with a bleeding event during the first 180 days were excluded. (7) The number of medications in use and the number of days in hospital during the baseline period were added to the multivariable model. (8) The main analyses were repeated for two individual statins, atorvastatin (C10AA05) and rosuvastatin (C10AA07).
As an external validation, we analysed the association between use of NSAIDs and the rate of bleeding in warfarin users.
Results
Altogether, 101,588 patients initiated warfarin use between 1 January 2009 and 30 June 2012 and accumulated a total of 152,928 person-years of warfarin exposure during the study period. Most patients (75,380 or 74.2%) had only one warfarin episode during the follow-up, 15,795 or 15.6% had two, and 4594 or 4.5% had four or more episodes.
The median age of the patients was 72 years at warfarin initiation (table 1) . Atrial fibrillation, followed by thromboembolic complications, was the most common indication of warfarin treatment. Cardiovascular comorbidities and polypharmacy were common, while malignant diseases (13,816 or 13.6%) and diagnosed liver diseases (1059 or 1.0%, data not shown) were less frequent. Proton pump inhibitors or H2-receptor blocking agents were used by almost onethird of the patients at warfarin initiation (30,896 or 30.4%).
The total person-time consisted of almost 93,000 personyears of exposure to warfarin-only and about 60,000 person-years of exposure to warfarin-with-statin (table 2) . In unadjusted analyses, male gender, older age, history of bleeding, hypertension, diabetes, heart failure, renal disease, dementia, alcohol abuse, rheumatic and gastrointestinal diseases were all associated with an increased rate of any bleeding in warfarin users. A high Charlson comorbidity index score, high number of medications in use and hospital days during the 365-day baseline period predicted higher rates of bleeding as well.
The rates of bleeding were 1.34 (1.26-1.41) per 100 person-years exposed to warfarin-only and 1.46 (1.36-1.56) per 100 person-years exposed to warfarin-with-statin (table 3) . Simvastatin was the most widely used statin, with the exposure comprising 71.0% of all person-years of exposure to warfarin-with-statins. In multivariable-adjusted analyses, no difference was found in the rate of any bleeding in association with exposure to any statin (RR 0.98, 95% CI 0.89-1.07) or to simvastatin (simvastatin: RR 1.01, 95% CI 0.91-1.11) with warfarin compared to exposure to warfarin-only.
Several sensitivity analyses were performed. Firstly, compared to the bleeding rate during warfarin-only person-time, the bleeding rate was more than doubled during person-time exposed to clopidogrel regardless of the concomitant statin exposure (table 4) . Secondly, when confounding by exposures to NSAIDs, SSRIs or clopidogrel was controlled by excluding the person-time exposed to these medications, and the RRs for exposure to warfarin-with-statins did not change appreciably compared to the main analysis (table S2) . In addition, when the person-time exposed to NSAIDs or SSRIs was removed from the analysis including use of warfarin, statins and/or clopidogrel, the results remained essentially the same as presented in table 4. Neither did defining the duration of a warfarin prescription as 111 days instead of 180 days, The number of bleeding events requiring hospitalization during 3820 person-years exposed to warfarin-with-any NSAID was 84, resulting in a crude bleeding rate of 2.21 (95% CI 1.76-2.74). Expectedly, the rate of bleedings was almost doubled (adjusted RR 1.78, 95% CI 1.43-2.22) during exposure to both warfarin and NSAIDs compared to warfarin-only. CI, confidence interval, py, person-years, GI, gastrointestinal disease, GORD, gastro-oesophageal reflux disease, RR, rate ratio. RRs reported for the presence versus absence of a characteristic unless otherwise stated. 1 Obtained from a model with a continuous age variable by multiplying the beta coefficient by 10.
Discussion
In this large nationwide cohort of warfarin initiators in Finland, neither did statins as a class nor simvastatin individually increase the rate of bleeding requiring hospitalization. This observation is of major clinical importance for many reasons.
Coprescribing of warfarin and statins is common, with concomitant use covering about 40% of the total person-time on warfarin in this study. The concomitant users are predominantly older people and, as seen also in this study, older age predisposes patients to bleeding complications. Concomitant use of warfarin and statins could lead to increased bleeding risk via various mechanisms. Statins may have direct antithrombotic effects of their own. Through their known effects on isoprenylation, statins may down-regulate the activity of the tissue factor or cause overexpression of thrombomodulin [23, 24] , both processes favouring anticoagulation. Furthermore, statins may inhibit platelet activation [23] . A large randomized trial showed that rosuvastatin 20 mg daily halved the risk symptomatic venous thromboembolism, in particular that of deep venous thrombosis, during a median follow-up of 1.9 years [25] . Reduction in venous thromboembolism after statin therapy has been observed also in some other [26, 27] but not all trials [28] . Furthermore, a meta-analysis of randomized, controlled trials including about 91,000 statin-treated patients found no evidence of increased intracerebral haemorrhage by statins, whereas ischaemic stroke and total mortality were significantly reduced by them [29] .
S-warfarin, the more potent enantiomer, is mainly metabolized by cytochrome P450 (CYP) 2C9 isoenzyme, whereas the R-enantiomer of warfarin is metabolized by CYP3A4 and 1A2 isoenzymes. Simvastatin tablets contain an inactive lactone form which is then hydrolysed to active simvastatin acid; both the lactone and acid form are metabolized by CYP3A4; the latter also through CYP2C8 [30] . A pharmacokinetic interaction between simvastatin or atorvastatin and warfarin is possible; both of these statins inhibited in vitro the metabolism of R-warfarin to 10-hydroxywarfarin [31] . Accordingly, when comparing the clearance of S-and R-warfarin in patients on warfarin alone and in those on warfarin and simvastatin, Sconce et al. [9] found a reduced clearance in patients using combination therapy. However, the calculation was based on oral administration only which makes the results susceptible to changes in drug absorption. Furthermore, genetic background may modulate the clinical importance of a potential warfarinsimvastatin interaction. The gene coding for CYP2C9 is polymorphic. Concomitant use of simvastatin reduced the warfarin dose in carriers of CYP2C9*3 allele by 29% but only by 5% in non-carriers; in heterozygotes for CYP2C9*3, the predicted reduction was 25% and in homozygotes 43% [32] .
Generally, DOACs are less prone to drug-drug interactions than warfarin. However, concomitant use of dabigatran with statins may be associated with increased incidence of bleeding. A nested case-control study among new users of dabigatran found that recent exposure to simvastatin and lovastatin was associated with an increased incidence of a major haemorrhage [33] . The reason may be pharmacokinetic; absorption of dabigatran is modulated by P-glycoprotein (ABCB1), and simvastatin, lovastatin and atorvastatin are considered to be inhibitors of P-glycoprotein [33, 34] . Apixaban and rivaroxaban are also substrates of P-glycoprotein [34] and are partly metabolized through CYP3A4 [35] but pharmacokinetic interactions with statins have not been reported as yet. Our study has strengths and limitations. We included virtually all patients using warfarin and statins outside the hospitals in Finland during the study period. As indicated by several sensitivity analyses, our main results were robust. While we did not have sufficient power to reliably estimate the associations for exposure to individual statins other than simvastatin, the point estimates for exposure to atorvastatin and rosuvastatin, which are our best guess of the magnitude of these associations, support our main result of no increase in the bleeding rates. Furthermore, we replicated the well-known increase in the bleeding risk in association with concomitant use of NSAIDs and warfarin which further increases confidence in our results. The completeness and accuracy of the Care Register for Health Care have been shown to be satisfactory overall and good regarding intracranial haemorrhage [36] . There are no validation studies for other types of bleeding events although, clinically, it seems reasonable to assume that major bleeding events are coded accurately. Due to reliance on register data, we did not know whether the dispensed medications were actually taken, and we were unable to adjust our analyses for use of the over-the-counter medications, such as aspirin and other non-prescription NSAIDs, and for some important comorbidities, including anaemia. In addition, there is potential for residual confounding due to underascertainment of measured comorbidities, including the Charlson comorbidity index. While we accounted for within-individual dependence between warfarin episodes in our analyses, we did not adjust for potential confounding by the order of warfarin episode. Finally, we did not adjust our analyses for concomitant use of CYP3A4 inhibitors or inducers. However, as reported previously, exposure to these medications was rare in our data (<0.5% of individuals in this cohort at warfarin initiation [2] and ≤0.5% of total person-time exposed to warfarin in 2010 [3] ).
We conclude that the use of statins together with warfarin was not associated with an increased rate of bleeding requiring hospitalization. Because of the widespread use of oral anticoagulants and statins in older people who are at increased bleeding risk, this observation is of major clinical importance.
